- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03330756
The Effects of the Laparoscopic Roux-en-Y Gastric Bypass and Laparoscopic Mini Gastric Bypass on the Remission of Type II Diabetes Mellitus (DIABAR)
November 8, 2017 updated by: Slotervaart Hospital
The Effects of the Laparoscopic Roux-en-Y Gastric Bypass and the Laparoscopic Mini Gastric Bypass on the Remission of Type II Diabetes Mellitus and the Pathophysiological Mechanisms That Drive the Conversion of Malign to Benign Obesity
It is estimated that there will be 439-552 million people with type 2 diabetes mellitus (T2DM) globally in 2030.
Type 2 Diabetes Mellitus is present in one quarter of patients at the bariatric outpatient clinic.
It is undecided which metabolic surgery grants best results in the remission of T2DM and which procedure does that at the lowest rate of surgical complications, long term difficulties and side effects.
Non alcoholic fatty liver disease (NAFLD) is present in 80% of all morbidly obese subjects and is a major risk factor for development of insulin resistance and non alcoholic steatohepatis (NASH).
It is increasingly recognized that the immune system, possibly driven by innate lymphoid cells (ILC's), and the intestinal microbiome are major players in this obesity related disease and the switch from benign to malign (insulin resistance and T2DM) obesity.
However, the exact mechanisms of action behind the surgery-driven switch back from malign to benign obesity are unknown.Primary objective is to evaluate and compare the glycaemic control in T2DM within the first year of LRYGB and LMBG.
Secondary aim is to gain insight in the pathophysiological mechanisms that drive the conversion of malign to benign obesity.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Metabolic surgery has proven to be a viable long-term solution in the treatment of morbid obesity and its comorbidities.
It induces rapid remission of type 2 diabetes mellitus (T2DM).
Type 2 Diabetes Mellitus is present in one quarter of patients at the bariatric outpatient clinic.
Non alcoholic fatty liver disease (NAFLD) is present in 80% of all morbidly obese subjects and is a major risk factor for development of insulin resistance and non alcoholic steatohepatis (NASH), with the latter becoming the major indication for liver transplantation in the USA.
It is increasingly recognized that the immune system, possibly driven by innate lymphoid cells (ILC's), and the intestinal microbiome are major players in this obesity related disease and the switch from benign to malign (insulin resistance and T2DM) obesity.
However, the exact mechanisms of action behind the surgery-driven switch back from malign to benign obesity are unknown.
Also, it is undecided which metabolic surgery grants best results in the remission of T2DM and which procedure does that at the lowest rate of surgical complications, long term difficulties and side effects.
The Laparoscopic Roux-en-Y Gastric Bypass (LRYGB), an efficient but complex procedure, is the golden standard in the Netherlands.
The Laparoscopic Mini Gastric Bypass (LMGB) is technically less challenging and has been introduced to overcome some of the limitations of LRYGB.
It has been hypothesized that the LMGB has a more rapid and durable glycaemic control, possibly due to the altered constitution and the augmented length of the biliary limb.
There is reason to believe that the improved glycaemic control might become apparent within the first year of surgery and that it might remain thereafter.
However, it is unknown what order of magnitude is to be expected and whether subgroups of T2DM patients will benefit the LMGB more.
Also, it is unknown whether and to what extent intestinal microbiota and immunological tone can predict the metabolic response (improvement in insulin sensitivity) and NAFLD/NASH reduction and whether differences are expected between these two surgeries.
Increased understanding of the pathophysiological mechanisms as well as their relationship to metabolic disturbances are thought to be of crucial importance to discover new diagnostic and therapeutical targets in obesity associated insulin resistance/T2DM and NAFLD/NASH.
Primary objective is to evaluate and compare the glycaemic control in T2DM within the first year of LRYGB and LMBG.
Secondary aim is to gain insight in the pathophysiological mechanisms that drive the conversion of malign to benign obesity.
Study Type
Interventional
Enrollment (Anticipated)
220
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Anne-Sophie van Rijswijk, MD
- Phone Number: +31205124460
- Email: anne-sophie.vanrijswijk@slz.nl
Study Contact Backup
- Name: Maurits de Brauw, MD PhD
- Email: maurits.debrauw@slz.nl
Study Locations
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1066EC
- Recruiting
- Medical Center Slotervaart
-
Contact:
- Anne-Sophie van Rijswijk, MD
- Phone Number: +31205014460
- Email: anne-sophie.vanrijswijk@slz.nl
-
Contact:
- Maurtis de Brauw, MD PhD
- Email: maurits.debrauw@slz.nl
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- BMI ≥35 and ≤50 kg/m2
- Diagnosis and treatment of T2DM at intake at bariatric ward with use of anti-diabetic medication.
- American Society of Anaesthesiologist Classification (ASA) ≤3
- All patients are required to lose 6 kilograms of weight prior to surgery
Exclusion Criteria:
- Known genetic basis for insulin resistance or glucose intolerance
- Type 1 DM
- Prior Bariatric surgery
- Patients requiring a concomitant intervention (such as cholecystectomy, ventral hernia repair)
- Auto-immune gastritis
- Known presence of gastro-esophageal reflux disease
- Known presence of large hiatal hernia requiring concomitant surgical repair
- Coagulation disorders (PT time > 14 seconds, aPTT ((dependent on laboratory methods) or known presence of bleeding disorders (anamnestic))
- Known presence of hemoglobinopathy
- Uncontrolled hypertension (RR > 150/95 mmHg)
- Renal insufficiency (creatinine > 150 umol/L)
- Pregnancy
- Breastfeeding
- Alcohol or drug dependency
- Primary lipid disorder
- Participation in any other (therapeutic) study that may influence primary or secondary outcomes
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Laparoscopic Roux-en-Y gastric bypass
|
laparoscopic Roux-en-Y gastric bypass with a 50 cm biliary limb and a 150 cm alimentary limb
Other Names:
|
Experimental: Laparoscopic Mini Gastric Bypass
laparoscopic Mini gastric bypass
|
laparoscopic Mini gastric bypass with a gastrojejunostomy at 200 centimeters measured from the ligament of Treitz
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
glycaemic control
Time Frame: 12 months FU
|
as measured by the difference in HBa1C
|
12 months FU
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
glycaemic control
Time Frame: 6 and 24 months FU
|
as measured by the difference in HBa1C
|
6 and 24 months FU
|
glycaemic control
Time Frame: 6, 12 and 24 months FU
|
as measured by the difference in HBa1C and anti-diabetic medication
|
6, 12 and 24 months FU
|
Insulin sensitivity
Time Frame: baseline, 12, 24 months FU
|
Mixed meal tolerance test for level of insulin sensitivity
|
baseline, 12, 24 months FU
|
NAFLD/NASH
Time Frame: day of surgery, reoperation
|
NAFLD/NASH parameters in liver biopsy measured with the Steatosis, Activity and Fibrosis (SAF) score according to Bedossa et al (2012).For each patient a SAF score summarizing the main histological lesions will be defined.
The steatosis score (S) will assess the quantities of larger or median-sized lipid droplets but not foamy microvesicules from 0 to 3 (S0 <5%; S1 5-33%; S2 34-66% and S3>67%).
Activity grade (A) from 0-4 is the unweighted addition of hepatocyte ballooning (0-2) and lobular inflammation (0-2).
Stage of fibrosis will be assessed using the score described by NASH-CRN as follows; stage 0 (F0) no fibrosis; stage 1 (F1) 1a or 1b perisinusoidal zone 3 or 1c portal fibrosis; stage 2 (F2) persinusoidal and periportal fibrosis without bridging; stage 3 (F3) bridging fibrosis and stage 4 (F4) cirrhosis.
A diagnostic algorithm which will be used during this study can be found in the original paper published by Bedossa et al.
|
day of surgery, reoperation
|
Presence of bacterial DNA/bacterial metabolites - portal vein
Time Frame: day of surgery, reoperation
|
in portal vein blood
|
day of surgery, reoperation
|
Presence of bacterial DNA/bacterial metabolites - liver
Time Frame: day of surgery, reoperation
|
in liver
|
day of surgery, reoperation
|
Presence of bacterial DNA/bacterial metabolites - abdominal adipose tissue
Time Frame: day of surgery, reoperation
|
in abdominal adipose tissue depots
|
day of surgery, reoperation
|
Expression and differentiation of intestinal immunological cells - GALT
Time Frame: day of surgery, reoperation
|
in GALT
|
day of surgery, reoperation
|
Expression and differentiation of intestinal immunological cells - abdominal adipose tissue
Time Frame: day of surgery, reoperation
|
in abdominal adipose tissue depots
|
day of surgery, reoperation
|
Expression and differentiation of intestinal immunological cells - liver
Time Frame: day of surgery, reoperation
|
in liver
|
day of surgery, reoperation
|
Expression and differentiation of intestinal immunological cells - peripheral blood
Time Frame: day of surgery, reoperation
|
in peripheral blood
|
day of surgery, reoperation
|
Expression and differentiation of immunological cells
Time Frame: 12 and 24 months FU
|
ILC's, macrophages
|
12 and 24 months FU
|
Expression and differentiation of inflammatory markers
Time Frame: 12 and 24 months FU
|
IL6, IRX3 and 5
|
12 and 24 months FU
|
Small intestinal and fecal microbiota composition
Time Frame: 2, and 6 weeks, 6 months, as well as 12 and 24 months after surgery
|
feces
|
2, and 6 weeks, 6 months, as well as 12 and 24 months after surgery
|
Peripheral blood inflammatory markers
Time Frame: 2, and 6 weeks, 6 months, as well as 12 and 24 months after surgery
|
ILC's, macrophages, T/B-cells and dendritic cells
|
2, and 6 weeks, 6 months, as well as 12 and 24 months after surgery
|
Eating habits
Time Frame: baseline, 12, 24 months FU
|
G-food craving questionnaire (FCQ-T) 21 item questionaire scale 0 (never) - 6 (always)
|
baseline, 12, 24 months FU
|
Eating habits
Time Frame: baseline, 12, 24 months FU
|
10 questions, scale 0-10 for instance 0 not hungry -10 very hungry / satiety / craving salty food / craving sweet food / craving fat food
|
baseline, 12, 24 months FU
|
Excreted metabolites
Time Frame: baseline, 12, 24 months FU
|
urine
|
baseline, 12, 24 months FU
|
Bio electric impedance
Time Frame: baseline, 12, 24 months FU
|
body composition as assesed by bioelectical impedance analysis (BIA): the measurement of body fat in relation to lean body mass.
|
baseline, 12, 24 months FU
|
Quality of life
Time Frame: baseline, 12, 24 months FU
|
Quality of life (IWQOL lite) 5 domain questionaire, 31 items: 1 never true - 5 always true
|
baseline, 12, 24 months FU
|
Cardiac / ventricular hypertrophy
Time Frame: baseline, 12, 24 months FU
|
Electrocardiogram (ECG)
|
baseline, 12, 24 months FU
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Maurits de Brauw, MD PhD, Head of department of Surgery
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 23, 2017
Primary Completion (Anticipated)
November 1, 2021
Study Completion (Anticipated)
November 1, 2021
Study Registration Dates
First Submitted
October 13, 2017
First Submitted That Met QC Criteria
October 30, 2017
First Posted (Actual)
November 6, 2017
Study Record Updates
Last Update Posted (Actual)
November 9, 2017
Last Update Submitted That Met QC Criteria
November 8, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P1729
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
-
Newsoara Biopharma Co., Ltd.RecruitingT2DM (Type 2 Diabetes Mellitus)China
-
Shanghai Golden Leaf MedTec Co. LtdActive, not recruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on laparoscopic Roux-en-Y gastric bypass
-
Instituto Nacional de Ciencias Medicas y Nutricion...Completed
-
CARLOS ZERRWECK LOPEZCompletedObesity | Bariatric Surgery Candidate | Type2 Diabetes | Laparoscopic Gastric BypassMexico
-
Kaunas University of MedicineUnknown
-
Puerta de Hierro University HospitalEnrolling by invitationPostoperative Complications | Weight Loss | Morbid ObesitySpain
-
University of PatrasCompletedType 2 Diabetes | Morbid Obesity | Bariatric SurgeryGreece
-
ClinTrio Ltd.UnknownMorbid Obesity Requiring Bariatric SurgeryBelgium, Germany, Portugal, Austria, Netherlands, Poland, Saudi Arabia
-
Asia Metabolic Surgery Research GroupE-DA HospitalUnknownType 2 Diabetes Mellitus - Poor ControlTaiwan
-
Hospices Civils de LyonRecruiting
-
Göteborg UniversitySuspendedQuality of Life | Obesity | Physical Activity | Bariatric Surgery | Post-operative ComplicationsSweden
-
Imperial College LondonCompletedObesity | Diabetes Mellitus, Type 2United Kingdom